The effects of liraglutide on beta-cell function and its mechanisms in young patients with new-onset type 2 diabetes

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800018008

Enrollment

Unknown

Registered

2018-08-27

Start date

2015-04-01

Completion date

Unknown

Last updated

2018-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Group 1:Liraglutide

Group 2:Metformin

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: The patients were initially diagnosed as type 2 diabetes according to World Health Organization criteria, aged 18-40 years, body mass index (BMI )of 25-35kg/m2, HbA1c 6.5 ~ 9%, without therapy for diabetes including diet and exercise, antidiabetes agents before the study.

Exclusion criteria

Exclusion criteria: Type 1 diabetes, recent acute complications including diabetic ketoacidosis and hyperglycaemic hyperosmolar coma, acute infection, impaired liver function, impaired renal function (creatinine clearance < 45 ml/min), women in pregnancy or lactation, smoker.

Design outcomes

Primary

Measure	Time frame
proinsuin;8-OH-dG;8-iso-PGF2a;hsCRP;Plasma insulin;	—

Countries

China

Contacts

Public ContactXiao-min Chen

Department of Endocrinology and Metabolism, Zhongshan Hospital Xiamen University

chenxiaomin0517@sina.com+86 13860487599

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026